Creo Medical Group PLC Commercial Launch of Speedboat at UEG Week (6700Q)
October 22 2019 - 2:00AM
UK Regulatory
TIDMCREO
RNS Number : 6700Q
Creo Medical Group PLC
22 October 2019
Creo Medical Group plc
("Creo" or the "Company")
Commercial Launch of Speedboat at UEG Week in Barcelona
Demonstration of wider suite of gastro-intestinal products
awaiting regulatory clearance
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces the
full commercial launch of its Speedboat device, the first in a
range of gastrointestinal ('GI') devices to be cleared for use with
the CROMA Advanced Energy platform which uniquely combines bipolar
radiofrequency energy for precise tissue dissection along with
microwave energy for highly controlled coagulation and tissue
ablation.
Creo will be exhibiting at the United European Gastroenterology
('UEG') Week Congress in Barcelona from 21-23, October 2019
show-casing the CROMA Platform, powered by its unique full spectrum
adaptive technology along with the GI suite of products for the
dissection, resection, haemostasis and ablation of soft tissue.
These products enable a wide variety of procedures, all of which
are targeting treatment in the endoscopy room instead of the
operating theatre wherever possible. This will be the first time
the suite of products will have been fully demonstrated to the
market as plans are put in place for first human cases.
Haemostasis device (HS1)* - is the ONLY non-stick haemostasis
device in any sphere of therapy which builds on the excellent
results seen clinically with the Speedboat device.
Resection device (RG1)* - is the ONLY bipolar RF scissors device
in any sphere of therapy powered by the unique full spectrum
adaptive technology in the CROMA platform. With capability to
simultaneously utilise RF and Microwave energy this device truly
brings laparoscopic surgical capability into the world of flexible
endoscopic surgery.
Narrow Probe ablation needle (NP1)* - is the SMALLEST microwave
ablation device in any sphere of therapy, providing precise and
accurate delivery of microwave energy for ablation of soft tissue
in various tissue types, ideal for the management of various GI
disease states
*internal nomenclature
The commercial launch of the CROMA platform and Speedboat, along
with the unveiling of a suite of devices at UEG Week is a major
milestone for the Company and comes as a growing number of GI
Endoscopists in the UK, mainland Europe, the US and South Africa
have successfully completed training via the Clinical Education
Programme and have now performed multiple successful procedures,
removing lesions in both upper and lower GI cases using the device.
The first commercial orders for Speedboat were announced in June
this year.
UEG Week is a great opportunity for researchers and companies to
present new research across a range of digestive disease areas and
combines world class scientific research, invited lectures by
leaders in gastroenterology and cutting-edge post-graduate teaching
sessions to cover topics to interest the entire GI community.
The event is organised by the UEG Society and will take place at
Fira Barcelona Gran Via, Barcelona, Catalonia, Spain. Creo Medical
will be exhibiting at booth 46 throughout the event.
Craig Gulliford, Chief Executive Officer, commented:
"The full commercial launch of the Speedboat device, coupled
with the opportunity to show-case the wider suite of products at
this key event, is another important step for the Company. In
addition to the profiling of our technology in the exhibition area,
we will also be using the time together with our distribution
partners throughout Europe to outline the initial roll out plans
for the wider portfolio and use this fantastic opportunity to build
further excitement and momentum as we head into 2020."
Creo Medical Group plc investors.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
(NOMAD)
Michael Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7515
909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform powered by
unique full spectrum adaptive technology to market enabling a suite
of medical devices which the Company has designed, initially for
the emerging field of GI therapeutic endoscopy, an area with high
unmet needs. The CROMA platform will be developed further for
bronchoscopy and laparoscopy procedures. The Company believes its
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option of
treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMTBATMBATMJL
(END) Dow Jones Newswires
October 22, 2019 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Aug 2023 to Aug 2024